Blood Disorders & Hematology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

This upcoming phase 3 trial will compare a new drug called surovatamig to the current standard treatment of radiotherapy, with or without rituximab, for adults with limited-stage nodal follicular lymphoma. The goal is to see if surovatamig can improve how well patients respond to treatment and lower the chance the cancer will come back. Although this study is not yet recruiting, it plans to include 138 participants, offering hope for more effective treatment options in the future.

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

This phase 1/2 trial explores a novel treatment using genetically modified T cells that target CD19, a protein found on some leukemia cells, for children and young adults with relapsed or hard-to-treat CD19+ acute leukemia. By harnessing the body’s immune system, this therapy aims to help patients who have not responded well to chemotherapy. The trial is active but not currently recruiting, and it includes patients who have previously undergone stem cell transplants.

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

This study offers a personalized approach by profiling the specific features of leukemia in children and young adults with recurrent or high-risk disease. Based on this detailed analysis, the trial recommends targeted treatments tailored to each patient’s cancer characteristics. The study is active but not recruiting, with results already available from multiple U.S. sites, potentially guiding future therapy choices for difficult-to-treat leukemias.

Novel Therapeutic Approach for Human T-cell Malignancies

This trial is testing a new treatment strategy focused on redox pathways for adults with T-cell leukemia or lymphoma, conditions that can be resistant to standard therapies. By targeting processes that affect cancer cell survival, the study hopes to find effective options for patients with these challenging diseases. It is currently recruiting in Italy and plans to enroll 120 participants.

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

This phase 2 study investigates a combination of chemotherapy drugs given before and after stem cell transplant in adults with various high-risk blood cancers. The goal is to reduce complications after the transplant and improve patient outcomes. The trial is actively recruiting in the United States and focuses on improving the transplant process for those with difficult blood cancers.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.